Description: Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
Home Page: www.anteristech.com
AVR Technical Analysis
Toowong Tower
Toowong,
QLD
4066
Australia
Phone:
61 13 0055 0310
Officers
| Name | Title |
|---|---|
| Mr. Wayne G. Paterson | CEO, MD & Exec. Director |
| Mr. Matthew McDonnell | Chief Financial Officer |
| Mr. David St. Denis | Chief Operating Officer |
| Mr. Stephen Denaro | Independent Non-Exec. Director & Company Sec. |
| Mr. Chris Olig | Bus. Devel. and Portfolio Planning Director |
| Dr. Chris Meduri M.D., M.P.H. | Chief Medical Officer & Member of Medical Advisory Board |
| Mr. Danny Zanardo | Commercial Director of International |
| Prof. Ian Hector Frazer AC, FAA, FRS, M.D. | Exec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.2602 |
| Price-to-Sales TTM: | 45.4182 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |